How stress hormone receptors alter the brain and behavior: Zebrafish study provides insights

Stress, the body's natural response to different types of challenges and daily problems, is an inherently harmless state ...

Scientists have learned about the effects of stress on the brain and behavior

Stress is the body's natural response to everyday difficulties and challenges, which can even be beneficial in the short term ...
Pharmaceutical Technology on MSN

Santhera grants Agamree rights to Nxera for DMD

Santhera Pharmaceuticals has entered into an exclusive licensing agreement with Nxera Pharma for Agamree to treat DMD in ...
Australian Associated Press

Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report

Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant ...
MedPage Today on MSN

GLP-1 Drug Market Changes; Wegovy Pill Hits Shelves; Hypercortisolism Drug Rejected

And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide ...
BioSpace

Crinetics Advances Potential Neurocrine Competitor With Fresh Data and Money

The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its ...
MedPage Today on MSN

CAR7 Gene Therapy Shows Promise in T-Cell ALL

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...
Scientific Research Publishing

Regulation Mechanisms and Research Advances of Cochlear Immune Microenvironment in Sensorineural Hearing Loss ()

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa ...

Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew ...
TMCnet

Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties

Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP. Pratteln, ...
Le Lézard

Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data

Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for ...